In the summer of 2014, the biggest activist hedge fund story on anyone’s lips was whether Bill Ackman had broken securities laws when he had accumulated a massive $3 bilion stake, or roughly 9.7% of the outstanding stock of Allergan (using leverage via call options), in advance of Valeant’s announcement it would launch a hostile offer for Allergan.